Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Hoffmann-La Roche
- Study ID
- NCT07177352
- Phase
- PHASE3
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
- No Intervention — OTHERParticipants will have their blood drawn and cognitive score measured by the ISLT.
Study Details
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Key Dates
- Start date
- Jul 2, 2025
- Status verified
- Jun 2026
- Primary completion
- Jul 31, 2035
- Completion
- Jul 31, 2035
Study Design
- Enrollment
- 13,000 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SCREENING
Arms
- Other: Screening ArmParticipants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT).
Primary Outcome Measure
Concentration of pTau217 in Blood on Day1 [ Time Frame: Day 1 ]
Central Contacts
- Reference Study ID Number: WP45722 https://forpatients.roche.com/888-662-6728 (U.S. and Canada)
Locations (68)
Find similar trials in Birmingham, AL
By condition
By specialty
Related Studies
- A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPHASE2/PHASE3 · Recruiting · Washington University School of Medicine · Birmingham, Alabama
- Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers DiseaseRecruiting · Emory University · Atlanta, Georgia
- Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's DiseasePHASE2 · Recruiting · Brigham and Women's Hospital · Boston, Massachusetts
- A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic MutationPHASE2/PHASE3 · Recruiting · Washington University School of Medicine · Birmingham, Alabama